AstraZeneca picks Oxford Biomedica to make potential COVID-19 vaccine

(Reuters) - AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.The vaccine, AZD1222, was developed by researchers at the University of Oxford and licensed to AstraZeneca. Oxford Biomedica, which was spun off from the university in 1995, on Thursday signed a one-year deal with AstraZeneca to provide multiple batches of the vaccine, which..